1 January 2022 in Vaccine
Hepatitis A virus (HAV) is a global health concern as outbreaks continue to occur. Since 1999, several countries have introduced universal vaccination (UV) of children against HAV according to approved two-dose schedules. Other countries have implemented one-dose UV programs since 2005; the long-term impact of this schedule is not yet known. We conducted a systematic literature search in four electronic databases for data published between January 2000 and July 2019 to assess evidence for one-dose and two-dose UV of children with non-live HAV vaccines and describe their global impact on incidence, mortality, and severity of hepatitis A, vaccine effectiveness, vaccine efficacy, and antibody persistence. Of 3739 records screened, 33 peer-reviewed articles and one conference abstract were included. Rapid declines in incidence of hepatitis A and related outcomes were observed in all age groups post-introduction of UV programs, which persisted for at least 14 years for two-dose and six years for one-dose programs according to respective study durations. Vaccine effectiveness was ≥95% over 3-5 years for two-dose programs. Vaccine efficacy was >98% over 0.1-7.5 years for one-dose vaccination. Antibody persistence in vaccinated individuals was documented for up to 15 years (≥90%) and ten years (≥74%) for two-dose and one-dose schedules, respectively. Experience with two-dose UV of children against HAV is extensive, demonstrating an impact on the incidence of hepatitis A and antibody persistence for at least 15 years in many countries globally. Because evidence is more limited for one-dose UV, we were unable to draw conclusions on immune response persistence beyond ten years or the need for booster doses later in life. Ongoing epidemiological monitoring is essential in countries implementing one-dose UV against HAV. Based on current evidence, two doses of non-live HAV vaccines are needed to ensure long-term protection.
25 June 2026 in BMC Public Health
DHDiana Harteveld-Griffioen
Diana Harteveld-Griffioen
MPMariska W.F. Petrignani
ASAdriënne S. van der Schoor
Adriënne S. van der Schoor
+5
Background: Avian Influenza (AI) is a potential pandemic threat, specifically when human-to-human transmission occurs. In order to mitigate potential outbreaks amongst humans, testing is essential. l. It is necessary to identify determinants of testing behaviour for AI in an early phase, as current knowledge on testing behaviour is mostly derived from other infectious diseases such as COVID-19. Therefore, this interview study aims to identify a wide range of behavioural determinants of diagnostic testing during a hypothetical human-to-human transmissible AI outbreak. Methods: Semi-structured in-depth interviews, based on the Theoretical Domains Framework, were carried out between May 2024 and February 2025. Participants were included through purposive and convenience sampling. During the interviews an animation was shown illustrating a hypothetical AI outbreak. Verbatim transcripts were thematically analysed. Results: We included seventeen participants (median age 44, range 20–81; 71% women) with diverse backgrounds in terms of age, gender, educational level and country of birth. Results show that, in this hypothetical setting, having the choice to test increases acceptance of testing, whereas a decreased sense of autonomy discourages testing. Most themes included individual rather than population-level benefits as drivers of testing behaviour. These included protecting loved ones, one’s own health and gaining psychological reassurance. External conditions such as being unable to go to work or an event would generally encourage testing behaviour. Lower trust in governmental authorities could hamper testing behaviour. Previous experiences from the COVID-19 pandemic shaped participants’ answers about AI testing behaviour. Conclusion: Key considerations include balancing people’s need for autonomy with the external measures imposed by employers or the government, rebuilding trust in institutions and acknowledging how prior experiences with testing may shape testing behaviour in future AI outbreaks. Further research is needed to determine how these findings can be translated into effective communication and how trust in authorities can be built.